From Wikipedia, the free encyclopedia

Combination of
CelecoxibNonsteroidal anti-inflammatory drug (NSAID)
Tramadol hydrochlorideOpioid agonist
Clinical data
Trade namesSeglentis
Other namesE-58425
License data
Routes of
By mouth
ATC code
Legal status
Legal status

Celecoxib/tramadol sold under the brand name Seglentis, is a fixed-dose combination of the anti-inflammatory celecoxib and the opioid tramadol used for the management and treatment of pain.[1]

Developed by Spanish pharmaceutical company Esteve, it was approved for medical use in the United States in October 2021.[1][2][3]


  1. ^ a b c "Seglentis- celecoxib and tramadol hydrochloride tablet". DailyMed. Retrieved 8 January 2022.
  2. ^ "Seglentis: FDA-Approved Drugs". U.S. Food and Drug Administration. Retrieved 18 October 2021.
  3. ^ "Esteve Announces FDA Approval Of A Novel Co-Crystal Form Of Celecoxib And Tramadol For The Management Of Acute Pain". Esteve (Press release). 15 October 2021. Retrieved 18 October 2021.

External links[edit]

  • "Celecoxib". Drug Information Portal. U.S. National Library of Medicine.
  • "Tramadol hydrochloride". Drug Information Portal. U.S. National Library of Medicine.
  • Clinical trial number NCT03108482 for "Co-crystal E-58425 vs Tramadol and Celecoxib for Moderate to Severe Acute Pain After Bunionectomy. Phase III Clinical Trial." at ClinicalTrials.gov